Bleeding and overanticoagulation with fondaparinux

The risk of bleeding during therapy with fondaparinux is increased by recent surgery or trauma, and other patient-associated factors for increased bleeding risk listed in Patient-associated factors that increase bleeding risk with anticoagulant therapy.

No specific antidote is available to manage bleeding caused by fondaparinux. If significant bleeding occurs, stop fondaparinux and provide supportive treatment. For life-threatening bleeding, consider giving activated prothrombin complex concentrate (or, if it is unavailable, recombinant factor VIIa); seek specialist haematologist adviceFrontera, 2016.